Geert Vanden Bossche’s Predictions on the Evolution of SARS-CoV-2 By Brian Simpson
One aspect of the Covid business not adequately discussed, apart from by Dr Geert Vanden Bossche, is where this plandemic will go with mass vaccination with a leaky vaccine, one which does not stop transmission of the virus. Dr Vanden Bossche goes back to basic evolutionary theory and shows that the mass vax programs have set in motion a breeding ground for highly resistance viruses. Add that to the decline in the immune system also produced by the vax, such as antibody dependent enhancement, and there is a medical disaster of epic proportions coming.
“"I SERIOUSLY expect that a series of new highly virulent and highly infectious SARS-CoV-2 (SC-2) variants will now rapidly and independently emerge in highly vaccinated countries all over the world and that they will soon spread at high pace. I expect the current pattern of repetitive infections and relatively mild disease in vaccinees to soon aggravate and be replaced by severe disease and death. Unfortunately, there is no way vaccinees can rely on assistance from their innate immune system to protect against coronaviruses as their relevant innate IgM antibodies are increasingly being outcompeted by infection-enhancing vaccinal Abs, which are continuously recalled due to the circulation of highly infectious Omicron variants. In contrast, Omicron’s high infectiousness would enable the non-vaccinated to train their innate immune defense against SC-2 while the infectious and pathogenic capacity of the new SC-2 variants would be debilitated in the non-vaccinated for lack of infection-enhancing Abs in their blood. Unless..."
Summary It cannot be denied that breakthrough infections with more infectious variants, including Omicron, have occurred as a result of vaccine-induced population-level immune pressure on spike protein (S)-specific neutralizing epitopes. It has been established that non-neutralizing antibodies (Abs) directed at epitopes comprised within the conserved ‘enhancing’ site within the N-terminal domain (NTD) of S (S-NTD) not only contribute to Omicron’s enhanced infectiousness in vaccinees but are also likely to mitigate disease as the course of Omicron infections is rather mild. It follows that highly vaccinated populations are now highly susceptible to contracting SC-2 (Omicron) infection and placing more and more immune pressure on the infection-enhancing site within the S-NTD to prevent Omicron from causing systemic disease. I posit that this immune pressure is now at risk of driving natural selection of new SC-2 variants (‘Newco variants’) that will be endowed with one or more O-glycosylation sites that can shield the conserved NTD region comprising the non-neutralizing enhancing epitopes and thereby escape the disease-mitigating effect exerted by the enhancing anti-NTD Abs in vaccinees. Hence, natural selection of mutations enabling more extensive O-glycosylation of spike protein would make new immune escape variants more virulent for vaccinees while shielding the receptor-binding domain (RBD) from potentially neutralizing vaccineinduced Abs directed at spike protein (S). As site-specific O-glycosylation of S would abrogate Abmediated protection against severe disease in vaccinees, Ab-dependent enhancement of viral infectiousness (ADEI) would now directly translate into Ab-dependent enhancement of C-19 disease (ADED) and full resistance to all potentially neutralizing vaccine-induced Abs directed at spike protein (S), thereby enabling an even higher level of viral infectiousness. This would ultimately result in a tsunami of hospitalizations and deaths in highly vaccinated populations whereas the unvaccinated would be better and better protected against the Newco variants thanks to their ‘enhanced’ (i.e., trained) innate immunity and because of reduced infectiousness and trans infectiousness of the virus in the upper and lower respiratory tract, respectively. As glycosylation of viral proteins responsible for initiation of infection are well known to evolve as a result of immune pressure on the viral life cycle, there is a high need for molecular epidemiology 7 Author: G. Vanden Bossche, DVM, PhD Update May 9th 2022 surveillance of SC-2 to not only monitor evolutionary changes in viral peptide sequences but to also perform glycosylation profiling and glycoproteomics of SC-2 spike protein (S). No ongoing pandemic can be tamed by vaccines that mitigate symptoms but cannot provide sterilizing immunity. At this stage, the only way to avert a large-scale disaster is to immediately replace the mass vaccination program by large scale antiviral chemoprophylaxis campaigns in highly vaccinated countries. Why this call? I know this is a bad time to share my deep concerns about the future evolution of this pandemic. I know the world is currently getting more than enough of very concerning news; in addition, scary predictions about the future evolution of this pandemic are never welcome. The only reason why I nevertheless continue to express my concerns is that I cannot refrain from urging national and international public health agencies to immediately engage their populations in large scale antiviral chemoprophylactic campaigns, especially in highly vaccinated countries. Given the high infectivity rate that characterizes the spread of Omicron, the rather ‘mild’ course of infections we are currently witnessing cannot be considered the endgame prelude of this pandemic. Even if the mass vaccination program were immediately halted, a spectacular and immediate reduction of viral infection rates in highly vaccinated populations would be required to prevent these populations from further exerting spike (S)-directed immune pressure on Omicron. Based on the analysis of molecular epidemiologists, there can be no doubt that convergent evolution of SC-2 towards protection of its life cycle from host immune attacks will continue for as long as these attacks will threaten the life cycle of the virus but not in ways that can fully prevent its replication and transmission. Because of strong selective immune pressure on viral infectiousness, the virus has already turned to expansion in prevalence of highly infectious variants as a mechanism to ensure its survival and to escape new immune attacks. As will be explained below, the evolution of SC-2 towards more virulent circulating variants directly results from the combination of its resistance to potentially neutralizing vaccinal Abs and the high level of infectiousness it achieves in highly vaccinated populations. It is, therefore, paramount that we stop mass vaccination and immediately reduce the infection rate in the population.”